10-Q quarterly report · filed Nov 3, 2026

STANDARD BIOTOOLS INC. (LAB) Q3 2026 10-Q Quarterly Report

Short answer

STANDARD BIOTOOLS INC. (LAB) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $19M (down 0.9% year over year) with net income of $13M.

Q3 2026 key financials · XBRL

Revenue
$19M
−0.9% YoY · −3.6% QoQ
Net income
$13M
+138.9% YoY · +150.4% QoQ
Operating margin
-102.0%
Gross margin
55.9%
EPS (diluted)
$0.03
+133.3% YoY · +142.9% QoQ

Source: XBRL data from the STANDARD BIOTOOLS INC. (LAB) Q3 2026 10-Q on SEC EDGAR. USD.

STANDARD BIOTOOLS INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $19.385M, down $0.167M or 1% YoY, with instruments up 18% to $5.998M
  • Gross margin 55.9% vs 48.5% YoY, gross profit $10.828M vs $9.484M
  • Services and other revenue weakest line, down 12% to $5.057M; consumables down 4% to $8.330M
  • Cash, cash equivalents and investments $559.4M vs $213.3M at December 31, 2025; operating cash use $63.1M
  • Merger expected in fourth quarter of 2026; liquidity expected sufficient for at least the next 12 months

Risk Factors

  • Merger agreement risk: representations and warranties expire at Closing, eliminating post-closing indemnification for undisclosed liabilities
  • Legal risk: July and August 2026 stockholder demands could delay or enjoin the Merger
  • CVR monetization risk: no payments if legacy-business proceeds, investment proceeds, contingent payments, and Parent Net Cash surplus are absent
  • Dilution risk: CVR settlements may issue up to 76,000,000 combined-company shares
  • Liquidity risk: unsecured CVRs are subordinated to senior obligations and lack an established trading market

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other STANDARD BIOTOOLS INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.